Would you offer zolbetuximab in a non-Asian population?

Neither GLOW nor SPOTLIGHT showed a statistically significant improvement in PFS/OS for non-Asian subgroups. It is reasonable to suspect that any PFS/OS benefit was driven by the Asian populations in the study. Even if the studies were not fully powered for this subgroup analysis, the similar findings in both trials raise questions as to the external validity across all populations.

Answer from: Medical Oncologist at Community Practice

Great question. Both studies suggested a discrepancy in benefits between white and Asian patients. However, these were subgroup analyses and neither study was powered to specifically detect a significant effect in white patients. Issues like this are frequently encountered in randomized clinical tri...

Comments

Medical Oncologist at Munson Medical Center
I appreciate the thoughts, but I think you simply ...

Please select the option that best describes you:

Would you offer zolbetuximab in a non-Asian population?

Related Questions